<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232024</url>
  </required_header>
  <id_info>
    <org_study_id>CHTF919D2301</org_study_id>
    <nct_id>NCT00232024</nct_id>
  </id_info>
  <brief_title>Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia</brief_title>
  <official_title>Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the safety, tolerability and satisfactory relief of
      dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will
      be evaluated at 6mg twice daily and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Over 6 weeks of treatment assessment of percent of days with satisfactory relief of dyspepsia and/or average severity score in (average of post-prandial fullness early satiety and bloating)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average severity score during each week.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of days with satisfactory relief of dyspepsia during each week.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly global assessment of change in dyspepsia condition.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily assessment of improvment of individual symptoms postprandial fullness early satiety, bloating, abdominal pain, nausea and vomiting.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at end of treatment compared to baseline.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability.</measure>
  </secondary_outcome>
  <enrollment>1296</enrollment>
  <condition>Dyspepsia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegaserod</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, 18 years or older

          -  Self-reported presence of persistent or recurrent adverse digestive symptoms
             consistent with dyspepsia for at least 12 weeks, not necessarily consecutive, during
             the previous 12 months.

        Exclusion Criteria:

          -  Abnormal upper GI endoscopy findings such as esophageal, gastric erosions or ulcers
             and/or duodenal ulcers/erosions.

          -  Any of the following symptoms: heartburn, epigastric pain, nausea or vomiting.

        Other protocol-defined inclusion/exclusion criteria may appl
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936-108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>October 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <last_update_submitted>January 31, 2008</last_update_submitted>
  <last_update_submitted_qc>January 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2008</last_update_posted>
  <keyword>Dyspepsia, gastrointestinal, tegaserod</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegaserod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

